NUCLEOLIN and leukemia: Thus, our findings highlight NCL as an innovative member of the epigenetic regulator family and offer a preclinical concept that targeting NCL-DNMT axis can significantly improve outcomes for leukemia patients with relapse or unresponsiveness to DNA hypomethylating agents.